“We are investing because we are capable of growth and want to grow”, Ralph Schmidt, CEO
Baden-Baden, Germany (PRWEB) November 29, 2012
While the German pharma industry as a whole adjusts to a stagnant market, the Baden-Baden pharmaceutical manufacturer Heel is experiencing increasing sales. According to CEO Ralph Schmidt, who spoke at a press conference earlier in November, the company is again on target to break its annual sales record. Heel is setting a course for sustained growth through investments in production, employees, research, and international markets.
In the current fiscal year, Biologische Heilmittel Heel GmbH – the world’s largest producer of homeopathic combination medications – is set to increase its annual revenue once again. After achieving 196 million euros in sales in 2011, CEO Ralph Schmidt is confident that the company will pass the 200 million mark to set a new record in 2012.
Each year, Heel produces approximately one billion tablets, 90 million ampules, 40 million suppositories, 10 million packages of liquid drops and sprays, and 4 million packages of ointments and gels, and the demand for natural medications is steadily increasing, as Schmidt explains: “In Germany alone, we are growing at an annual rate of approximately 6 percent, in spite of an overall stagnant market.” 70 percent of the pharmaceutical company’s sales are generated abroad. The medications Heel develops on the basis of natural active ingredients are available in over 50 countries and are offered worldwide by the company’s subsidiaries and distribution partners. The CEO sees markets in the Americas and Eastern Europe as the main growth drivers. “In countries like Russia or Colombia, we are currently achieving above average increases,” says Schmidt. “We are investing because we are capable of growth and want to grow.”
“To meet increasing international demand and to maintain our company’s growth course, we are doing pioneering work on many different levels,” states Schmidt confidently. The CEO points to the accomplishments of the company’s Baden-Baden location, where investment has been consistently high: over 10 million euros per year, for a total of 80 million euros in the last five years. “We are investing because we are capable of growth and want to grow.” Schmidt explains the connection: “The continued upward trend requires expansion of our capacities.” For example, the acquisition of six new machines for the processing and packaging lines has doubled the Baden-Baden location’s tablet production capacity. The innovative technology of two new ampules labeling machines will ensure that Heel’s production will be even faster, simpler, and more precise going into the future.
Heel also claims other pioneering accomplishments for itself. To study the efficacy of its own products, the company uses the very latest medical and scientific methods (derived from genome research, for example), invests tens of millions of euros annually for that purpose, and is involved in 50 research projects in collaboration with international experts, institutes, and universities. Only recently, scientists conducting a large-scale clinical study of 450 patients demonstrated that one of the company’s own products was just as effective as therapy for sprained ankles as the widely known anti-inflammatory drug diclofenac, which is included in many brand-name products such as Voltaren.
Good prospects for employees
Producing medications to high standards of quality requires highly qualified personnel. “It is becoming increasingly difficult to find qualified professionals. We have had to increase our search radius repeatedly,” states Schmidt. That is why Heel is now investing even more heavily in its employees. Its life-stage oriented personnel policies are based on individualized programming and cater to employees’ needs. The primary focus, combining family and career, is complemented by health management initiatives, company-sponsored retirement benefits, and long-term care benefits for dependents. In 2010, the company’s headquarters added a daycare center for infants and toddlers staffed with professional day-care providers.
The education of young adults has also been an important subject at Heel for years. “We count on growing our own successors and have been awarded multiple prizes for the high quality of our training programs,” emphasizes Schmidt. With 800 of its 1,400 international workers located in Baden-Baden, Heel is one of the region’s largest employers. Since 2007, the company has offered career opportunities to more than 100 young people.
Heel is a pharmaceutical company that develops, manufactures and distributes medicines based on natural substances. As the global leader in homeopathic combination preparations, the company is also a pioneer in the field of scientific research in natural healthcare. In cooperation with academic institutions, Heel actively fosters the concept of integrative medicine and is building the bridge between homeopathy and conventional medicine to improve patient care and health.
Biologische Heilmittel Heel GmbH, with corporate headquarters located in Baden-Baden/Germany and a staff of 1,300, achieved an annual turnover of 196 million euros in 2011 – 70 percent of it outside of Germany. Heel medicines are available through subsidiaries and distribution partners in over 50 countries around the world. http://www.heel.com